Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Frank Buck who wrote (1517)	3/10/1998 11:35:00 PM
From: Sigmund	Read Replies (1) \| Respond to of 1894

Financially it would make a lot of sense. Realistically I wonder if NSIX can abandon their product and the officers still keep their jobs. But why lose $8mm per quarter when they can call it quits and exploit what ACMIC has in the pipeline. The better deal I think is Cytyc. I believe, correct me if I am wrong, that ACYT has both a thin prep slide and a slide reader under review by the FDA with the slide about to be approved. I don't know much about the slide reader but I assume it is designed to compete with AutoPap. Do you know anything about this? If this is correct then to some extent ACYT leapfrogs CYTC at least theoretically in terms of scope of solution. Wouldn't cooperation between ACMIC and CYTC then put CYTC ahead of or even with ACYT? It may be too soon for CYTC to see the need for this. But this is where an investment banker might earn their substantial fees. On a different subject some regional bank announced today biz.yahoo.com that they are being delisted and their stock went up. They thought that saving the $4000 annual filing fee was a good idea among other arguments for accepting the delisting.